STOCK TITAN
  1. Home
  2. News
  3. CLRB

Cellectar Biosciences Inc - CLRB STOCK NEWS

Welcome to our dedicated news page for Cellectar Biosciences (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cellectar Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cellectar Biosciences's position in the market.

News
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) announced positive financial results for 2023 and provided a corporate update, highlighting significant progress in its pivotal study of iopofosine I 131 in Waldenstrom’s macroglobulinemia. The company reported a major response rate of 61% in relapsed/refractory patients, with durable responses and high rates of disease control. Additionally, Cellectar achieved a complete remission rate of 64% in head and neck cancer patients and demonstrated complete clonal clearance in a patient with Bing-Neel Syndrome. The company also initiated a Phase 1b study in pediatric high-grade gliomas and presented promising preclinical data for CLR 121255 in pancreatic cancer models. Cellectar expanded its IP protection and successfully exercised Tranche A warrants, raising approximately $44.1 million. Financially, the company had $9.6 million in cash and cash equivalents as of December 31, 2023, with a net loss of ($38.0) million for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
earnings
-
News
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) will release its financial results for the year ended December 31, 2023, on March 27, 2024. The company, specializing in cancer treatment drugs, will host a conference call at 8:30 am Eastern Time to discuss the results with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
earnings
-
News
Cellectar Biosciences to Present at the 36th Annual Roth Conference
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) announces Jim Caruso, the President and CEO, will present at the 36th Annual Roth Conference. The presentation will focus on the company's overview and future prospects in cancer drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
conferences
News
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) announces positive results from a Phase 1 clinical trial showcasing a 64% complete remission rate and a 73% overall response rate in highly refractory patients with head and neck squamous cell carcinoma. The study also highlights a 67% overall survival and a 42% progression-free survival at one year. The combination of iopofosine I 131 with external beam radiation therapy was well-tolerated, showing promising therapeutic effects without significant toxicity increase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
clinical trial
-
News
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced that James Caruso, president and CEO, will present an overview of the company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will be held virtually on February 14, 2024, at 2:00 – 2:30 pm Eastern Time. A webcast will be available, and a replay can be accessed on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
-
News
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) has announced the enrollment of the first patient in its Phase 1b clinical trial for iopofosine I 131, a novel phospholipid radiotherapeutic conjugate, in pediatric patients with relapsed or refractory malignant high-grade gliomas (pHGG). The study is supported by a $2 million Fast Track SBIR grant from the National Institute of Health’s National Cancer Institute (NCI). The company aims to identify the optimal iopofosine I 131 Phase 2 recommended dose and schedule in pHGG patients and evaluate safety and tolerability. The treatment has shown promising results in a relapsed, refractory Bing-Neel Syndrome patient and demonstrated clinical activity across the blood-brain barrier in other hematologic malignancies. Cellectar is hopeful that its novel mechanism of action will provide a meaningful treatment option for pediatric patients with high-grade gliomas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
clinical trial
News
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced the full exercise of Tranche A warrants from a previous private placement, resulting in gross proceeds of approximately $44.1 million. Additionally, the company issued Tranche B warrants for potential aggregate proceeds of approximately $34.3 million. The Tranche B warrants contain a trigger for investors to exercise following the Company's public announcement of its receipt of written approval from the U.S. FDA of its New Drug Application (NDA) for iopofosine I 131, or September 8, 2028. The president and CEO, James Caruso, expressed confidence in the company's lead asset, iopofosine I 131, and highlighted the strengthened balance sheet and investor support for achieving near-term milestones, including NDA submission and potential accelerated FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
none
-
News
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
Rhea-AI Summary
Cellectar Biosciences, Inc. announces successful pathological response with complete clonal clearance in a patient with relapsed/refractory Waldenstrom’s macroglobulinemia (WM) and CNS involvement using iopofosine I 131. This validates the potential of the drug to treat CNS malignancies, including CNS lymphoma and pediatric high-grade gliomas. The company has also initiated a Phase 1b study in pediatric high-grade gliomas with the support of a $2 million grant from the National Cancer Institute.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.6%
Tags
none
-
News
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
Rhea-AI Summary
Cellectar Biosciences, Inc. announced promising preclinical data for its proprietary novel alpha-emitting phospholipid radiotherapeutic conjugate, CLR 121225, in pancreatic cancer models. The compound demonstrated potent anti-tumor activity in refractory pancreatic cancer mouse xenograft models, with a single administration resulting in tumor volume reduction in a dose-dependent manner. The data also showed excellent biodistribution and good tolerability, supporting the continued development of CLR 121225 for a Phase 1 first-in-human study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
clinical trial
News
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) to Host Conference Call with Dr. Levy to Discuss Positive Results of Iopofosine I 131 in Waldenstrom's Macroglobulinemia Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
conferences clinical trial
Stock CLRB logo
Cellectar Biosciences Inc

Nasdaq:CLRB

CLRB Rankings

#4293 Ranked by Market Cap
#1026 Ranked by Stock Gains
N/A Ranked by Dividends

CLRB Stock Data

113.23M
24.62M
3.57%
30.47%
7.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Florham Park

About CLRB

cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p